A gut-lung connection influences susceptibility to infection by Acinetobacter baumannii, a leading cause of hospital-acquired ...

November 4, 2009 (Philadelphia, Pennsylvania) — Multidrug-resistant (MDR) Acinetobacter baumannii (ACBA) is a persistent threat to hospitalized patients, whether the infection is acquired in the ...

A gut-lung connection influences susceptibility to infection by Acinetobacter baumannii, a leading cause of hospital-acquired ...

New research has shown that a lack of dietary zinc can boost the chances of a lung infection caused by Acinetobacter baumannii bacteria; these pathogens are a major reason why people on ventilators ...

A research team has discovered a fundamental mechanism that helps the dreaded hospital pathogen Acinetobacter baumannii to survive. This mechanism explains why the pathogen is difficult to eradicate ...

A new study from Vanderbilt Health and the University of Chicago finds that antibiotics can disrupt gut microbiota, weakening lung immune defenses and worsening hospital-acquired pneumonia caused by ...

Credit: Getty Images. A PDUFA target date of May 29, 2023 has been set for the application. The Food and Drug Administration’s (FDA) Antimicrobial Drugs Advisory Committee unanimously voted 12-0 in ...

Acinetobacter baumannii represents a formidable nosocomial pathogen, largely due to its rapid acquisition of multidrug resistance and its capacity to cause severe infections. This Gram‐negative ...

Researchers discovered an unexpected link between zinc deficiency, the pro-inflammatory cytokine interleukin-13 (IL-13), and Acinetobacter baumannii lung infection and demonstrated that blocking IL-13 ...

XACDURO is a new FDA-approved treatment used to fight against HABP/VABP infections caused by isolates of Acinetobacter baumannii-calcoaceticus complex, which can include those resistant to carbapenems ...